Assessment of Effectiveness and Safety of Transcranial Magnetic Stimulation (rTMS) Combined With Transcranial Direct Current Stimulation (tDCS) in Dementia Treatment in Alzheimer's Disease
NCT ID: NCT04823819
Last Updated: 2021-05-27
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
40 participants
INTERVENTIONAL
2021-04-01
2023-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The medications currently used in Alzheimer's disease were introduced in the 1990s and exhibit insufficient effectiveness. Despite their use, the disease rapidly progresses, leading to complete loss of independence and death. There are conducted numerous studies on new molecules, however none of them has been successfully accomplished so far. Transcranial magnetic stimulation (TMS) is one of the youngest electrophysiological methods, enabling non-invasive and painless stimulation of the central and peripheral nervous system. Another non-invasible neurophysiological method that is utilized in treating patients with neurological dysfunctions and mental disorders is Transcranial direct current stimulation (tDCS). Clinical trials conducted with isolated usage of rTMS and tDCS showed a positive effect of these methods on the enhancement of cognitive functions in patients with Alzheimer's disease.
The aim of the project is to evaluate the effectiveness and safety of the combination of Repetitive Transcranial Magnetic Resonance (rTMS) with Transcranial direct current stimulation in the treatment of Alzheimer's dementia. The primary goal of the project is to assess whether the use of combined tDCS and rTMS therapies in patients diagnosed with mild to moderate Alzheimer's disease improves patients' cognitive functions, including memory, attention, thinking, executive and language functions. The research hypothesis assumes that the combination of rTMS and tDCS therapy is an effective method of Alzheimer's disease therapy that can improve cognitive functions and functioning of patients, both in the short and long term.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Repetitive Transcranial Magnetic Stimulation in Patients With Alzheimer Disease
NCT03270137
TMS in Preclinical and Prodromal AD: Modulation of Brain Networks and Memory
NCT04294888
Network-based rTMS in Alzheimer's Disease
NCT04263194
Repetitive Transcranial Magnetic Stimulation With H-coil in Alzheimer's Disease
NCT04562506
Acute Effect of Low-intensity Gamma rTMS on Cognitive and EEG Parameters in Adults With Mild Dementia by Alzheimer's Disease
NCT05784298
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
rTMS stimulation
20 sessions of stimulation with increasing intensity, reaching maximum in the 4th session.
Magnetic Stimulator DuoMag
Stimulation of the left dorsolateral prefrontal cortex
tDCS stimulation
The stimulation time will be 20 minutes, the current intensity will be 2mA.
neuroConn DC-STIMULATOR
One electrode (anode) will be placed on the left dorsolateral prefrontal cortex, the other (cathode) on the right temporal lobe.
Sham rTMS stimulation
20 sessions of stimulation, but without current.
Magnetic Stimulator DuoMag
Stimulation of the left dorsolateral prefrontal cortex
Sham tDCS stimulation
The stimulation time will be 20 minutes, but without current.
neuroConn DC-STIMULATOR
One electrode (anode) will be placed on the left dorsolateral prefrontal cortex, the other (cathode) on the right temporal lobe.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Magnetic Stimulator DuoMag
Stimulation of the left dorsolateral prefrontal cortex
neuroConn DC-STIMULATOR
One electrode (anode) will be placed on the left dorsolateral prefrontal cortex, the other (cathode) on the right temporal lobe.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* MMSE score from 12 to 26 points
* ADAS-Cog over 17 points
* Voluntary consent to participate in the study
* there is a related person or legal guardian who consented to assist the patient in the course of the study
* Minimum 8 years of education.
* It is allowed to use cholinesterase inhibitors and / or memantine for at least 3 months prior to study entry and at a stable dose for at least 60 days prior to study entry.
Exclusion Criteria
* Intellectual Disability
* Informed consent is not possible
* Unstable somatic condition
* Use of benzodiazepines or barbiturates 2 weeks prior to screening
* Participation in a clinical trial with coinciding factors within 6 months prior to the start of the trial
* Seizures
* Contraindications to rTMS treatment according to the rTMS questionnaire attached to the protocol
* Contraindications to tDCS treatment according to the tDCS questionnaire attached to the protocol
* Patients with depression, bipolar, or psychotic disorders, or any other neurological or psychiatric condition (current or past) that the Investigator considers to be interfering with the study
* Alcoholism or drug addiction as defined by DSM-5 in the last 5 years (addicted for more than a year and or in remission for less than 3 years)
* Patients with any medical condition that the Investigator considers to be an exclusion criterion from the study
55 Years
90 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Medical University of Lodz
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Jakub Kazmierski
PhD
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Jakub Kazmierski, PhD
Role: PRINCIPAL_INVESTIGATOR
Medical University of Lodz, Poland
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Department of Old Age Psychiatry and Psychotic Disorders Medical University of Lodz
Lodz, , Poland
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
RNN/246/20/KE
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.